US Defense Secretary Pete Hegseth announced on July 15, 2026, that the US military will institute an annual testosterone screening program for service members aged 30 and older, while permitting those under 30 to opt in. Al Jazeera

Hegseth delivered the announcement via a video message posted on X, formerly Twitter. The screening will be integrated into the periodic health assessment that US troops already complete each year. Any resulting treatment, including testosterone replacement therapy, remains the individual service member's choice, according to Hegseth. Al Jazeera

In his framing, Hegseth said the initiative is "not about artificial enhancement" but about "restoring and optimising your natural capabilities, protecting your longevity, ensuring you have the biological foundation required to sustain the fight." He stated the enhanced testosterone deficiency screening protocol is intended to "combat Operator Syndrome" among service members. Al Jazeera; US Department of Defense

The policy rollout traces back to a legislative prod. The Fiscal Year 2025 National Defense Authorization Act included a provision requiring the defense secretary to brief Congress on available treatments for low testosterone and existing testing and screening protocols. Al Jazeera

Lawmakers have responded with sharp critiques and counter-proposals. Senator Tammy Duckworth criticized the testosterone screening announcement, characterizing it as sounding "like gender-affirming care to me." Representative Chrissy Houlahan said the announcement "proves that Secretary Hegseth takes direction from the far corners of the manosphere." Al Jazeera

Both Duckworth and Houlahan called for hormone screening to be extended to women in uniform, citing elevated infertility rates among military personnel. Al Jazeera

The broader context here involves the tension between force readiness and medical autonomy. By embedding testosterone screening within the existing periodic health assessment, the Defense Department is normalizing endocrine monitoring as a routine force-readiness metric. Hegseth's framing, which emphasizes sustaining "the biological foundation required to sustain the fight," positions hormonal baseline tracking as a matter of operational longevity rather than individual wellness.

Yet the voluntary nature of treatment introduces friction. If a service member screens low, declining testosterone replacement therapy has no stated career consequence, but that could shift. Military medicine has long managed the line between fitness standards and personal medical choice. Whether routine hormone data becomes a factor in fitness evaluations, deployment eligibility, or command climate remains an open institutional question.

The legislative dimension also matters. The NDAA provision did not mandate screening; it required a briefing on protocols and treatments. Hegseth's announcement converts a congressional information request into an actionable policy. That move gives lawmakers leverage to probe implementation, including whether the program's scope is medically justified or ideologically driven, as Duckworth and Houlahan suggest.

The call from Duckworth and Houlahan to extend hormone screening to women, grounded in military infertility rates, reframes the debate from a critique of Hegseth's priorities into a demand for parity in force-wide reproductive and endocrine health. If that demand gains traction, it could broaden the policy into a comprehensive hormonal health initiative.

What comes next will hinge on the specifics of implementation: screening thresholds, medical referral pathways, data privacy protections, and how the military medical system handles the opt-in tier for under-30s. Congress will likely press for those details in oversight hearings. For now, the policy is announced, not yet operational.